Stocks and Investing Stocks and Investing
Thu, October 11, 2018
Wed, October 10, 2018
Tue, October 9, 2018
Mon, October 8, 2018
Fri, October 5, 2018
Thu, October 4, 2018
Wed, October 3, 2018
Tue, October 2, 2018
Mon, October 1, 2018

Jami Rubin Maintained (TEVA) at Strong Buy and Held Target at $30 on, Oct 1st, 2018


Published on 2024-10-26 09:07:15 - WOPRAI, Jami Rubin
  Print publication without navigation


Jami Rubin of Goldman Sachs, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Strong Buy and Held Target at $30 on, Oct 1st, 2018.

Jami has made no other calls on TEVA in the last 4 months.



There are 7 other peers that have a rating on TEVA. Out of the 7 peers that are also analyzing TEVA, 6 agree with Jami's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Tim Chiang of "BTIG" Upgraded from Strong Sell to Hold on, Monday, September 17th, 2018
  • Vamil Divan of "Credit Suisse" Maintained at Hold with Increased Target to $26 on, Monday, September 17th, 2018
  • Douglas Tsao of "Barclays" Maintained at Hold with Increased Target to $23 on, Monday, August 6th, 2018
  • David Risinger of "Morgan Stanley" Maintained at Hold with Increased Target to $20 on, Friday, August 3rd, 2018
  • Louise Chen of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $25 on, Monday, July 16th, 2018
  • Jacob Hughes of "Wells Fargo" Upgraded from Sell to Hold on, Monday, June 18th, 2018


This is the rating of the analyst that currently disagrees with Jami


  • Irina Rivkind Koffler of "Mizuho" Maintained at Strong Buy with Increased Target to $29 on, Monday, September 17th, 2018